Riptide Bioscience
Riptide Bioscience develops engineered peptides derived from host defense peptides found widely in nature. Their focus is on creating peptide-based therapeutics for cancer, inflammatory diseases, and microbial infections, especially those resistant to conventional treatments. The company advances both preclinical and early-stage clinical programs, collaborates with academic partners and government agencies, and holds patents for its engineered peptide design technologies.
Industries
Nr. of Employees
small (1-50)
Patents
Products
Engineered peptide therapeutics for acute infection
Synthetic peptides derived from host-defense peptide structures designed for high-potency, broad-spectrum antimicrobial activity and biofilm penetration; intended for topical treatment of wounds, burns, and localized infections.
Engineered peptide therapeutics for inflammation modulation
Peptide candidates designed to moderate inflammatory responses and restore tissue balance in chronic inflammatory conditions.
Preclinical oncology peptide candidates
Designed lytic peptides with documented anticancer activity in preclinical studies intended for oncology indications.
Engineered peptide therapeutics for acute infection
Synthetic peptides derived from host-defense peptide structures designed for high-potency, broad-spectrum antimicrobial activity and biofilm penetration; intended for topical treatment of wounds, burns, and localized infections.
Engineered peptide therapeutics for inflammation modulation
Peptide candidates designed to moderate inflammatory responses and restore tissue balance in chronic inflammatory conditions.
Preclinical oncology peptide candidates
Designed lytic peptides with documented anticancer activity in preclinical studies intended for oncology indications.
Expertise Areas
- Peptide therapeutic development
- Antimicrobial therapeutics
- Anti-inflammatory therapeutics
- Oncology therapeutics (peptide-based)
Key Technologies
- Synthetic peptide design and optimization
- Membrane-targeting antimicrobial mechanism
- Biofilm penetration assays
- In vitro antimicrobial and anticancer assays
Key People
President
Executive Vice President – Drug Design
Principal Scientist
Principal Scientist
President
Executive Vice President – Drug Design
Principal Scientist
Principal Scientist
News & Updates
Received the highest award at the Military Health Systems Research Symposium for antimicrobial research.
Study demonstrated the use of radiolabeled peptides for PET imaging of tumor-associated macrophages in a colon cancer model.
CD206-targeted peptide compared favorably with FDA-approved antifibrotic therapies in mouse models.
Peer-reviewed publication reports on efficacy of an engineered peptide in a mouse model for diabetic wound healing.
Science Translational Medicine article establishes CD206 as a novel immune checkpoint for modulating macrophages.
Antimicrobial peptides effectively treated antibiotic-resistant acne vulgaris in preclinical testing.
Received the highest award at the Military Health Systems Research Symposium for antimicrobial research.
Study demonstrated the use of radiolabeled peptides for PET imaging of tumor-associated macrophages in a colon cancer model.
CD206-targeted peptide compared favorably with FDA-approved antifibrotic therapies in mouse models.
Peer-reviewed publication reports on efficacy of an engineered peptide in a mouse model for diabetic wound healing.
Science Translational Medicine article establishes CD206 as a novel immune checkpoint for modulating macrophages.
Antimicrobial peptides effectively treated antibiotic-resistant acne vulgaris in preclinical testing.